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Abstract
Background—Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that typically 
results in death within 2–5 years of initial symptom onset. Multidisciplinary ALS clinics (MDCs) 
have been established to provide specialty care to people living with the disease.
Objective—To estimate the proximity of ALS prevalence cases to the nearest MDC in the US to 
help evaluate one aspect of access to care.
Methods—Using 2013 prevalence data from the National ALS Registry, cases were geocoded by 
city using geographic information system (GIS) software, along with the locations of all MDCs in 
operation during 2013. Case-to-MDC proximity was calculated and analyzed by sex, race, and age 
group.
Results—During 2013, there were 72 MDCs in operation in 30 different states. A total of 15,633 
ALS cases were geocoded and were distributed throughout all 50 states. Of these, 62.6% were 
male, 77.9% were white, and 76.2% were 50–79 years old. For overall case-to-MDC proximity, 
nearly half (44.9%) of all geocoded cases in the US lived >50 miles from an MDC, including 
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approximately a quarter who lived >100 miles from an MDC. There was a statistically significant 
difference between distance to MDC by race and age group.
Conclusions—The high percentage of those living more than 50 miles from the nearest 
specialized clinic underscores one of the many challenges of ALS. Having better access to care, 
whether at MDCs or through other modalities, is likely key to increasing survivability and 
obtaining appropriate end-of-life treatment and support for people with ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's 
disease, is a progressive, fatal neurodegenerative disorder that causes the loss of motor 
neurons, typically resulting in paralysis, respiratory failure, and death within 2–5 years of 
symptom onset (1). Despite ALS being initially identified in 1869, the actual pathogenesis 
and cause(s) remain unknown for the approximate 90% of sporadic cases and there is 
currently no cure. Additionally, because ALS, like most non-communicable diseases, is not a 
notifiable disease in the United States (US), the epidemiology of ALS has been difficult to 
accurately access, particularly on a national level.
To help address the epidemiology of ALS in the US, the federal Agency for Toxic 
Substances and Disease Registry (ATSDR) launched the congressionally-mandated 
population-based National ALS Registry (Registry) in 2010. Briefly, the main goals of the 
Registry are to quantify the incidence and prevalence of ALS in the US, describe the 
demographics of persons with ALS, and examine potential risk factors for the disease (2). 
Recent findings estimate that almost 16,000 Americans, or 5/100,000, lived with the disease 
in 2013 (3) and approximately 5000, or 1.5/100,000, are diagnosed annually (4).
Because ALS is a terminal disease with limited care options, multidisciplinary ALS clinics 
(MDCs) have been established over the past few decades as a means to provide symptomatic 
and palliative care specifically to patients with ALS (5). MDCs, considered by many as the 
gold standard of ALS care, are located in large metropolitan areas and contain various ALS 
experts and services that can help meet the needs of people living with the disease (e.g. 
neurologists, occupational/physical therapists, dietitians, gastroenterologists, respiratory 
therapists, speech-language pathologists, and social workers). Typically, ALS patients who 
use MDCs travel to, and spend at least one full day a quarter at, these facilities to obtain 
comprehensive care.
While the effects on survival from MDCs have largely been positive (6–11), there have been 
other studies yielding mixed results (12,13). The purpose of this paper is not to debate the 
effectiveness of MDCs, nor to minimize the treatment ALS patients receive at non-MDCs 
(e.g. via their local primary care physician or neurologist), but to provide a spatial 
representation of ALS prevalence cases and MDCs in the US to help determine one aspect of 
access to care.
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Materials and methods
The National ALS Registry
In 2008, the US Congress passed the ALS Registry Act (US Public Health Service Act) (14). 
This Act allowed for the creation of the National ALS Registry to collect and analyze data 
regarding persons living with ALS in the US. Because ALS is non-notifiable in the US 
(meaning physicians are not required to report newly diagnosed or existing cases to local 
and state government agencies, which in turn notify federal agencies), ATSDR's Registry 
uses a novel two-pronged approach for case ascertainment, which has previously been 
described (15). Briefly, the first approach applies a pilot tested algorithm to large national 
databases (e.g. Medicare, Veterans Health Administration) to identify cases, while the 
second approach uses a secure web-portal to allow people with ALS to self-identify to 
capture cases not identified in the first approach. Cases from both approaches are then 
merged and de-duplicated to ensure that cases are not counted twice. All activities involving 
the National ALS Registry have been reviewed and approved by the Institutional Review 
Board (IRB) of the Centers for Disease Control and Prevention (CDC)/ATSDR.
Study population
For this analysis, the 15,908 prevalent cases identified through ATSDR's 2013 ALS 
surveillance report were used (3). These cases, covering the entire US, reflect the most 
recent year for which national data are available. The 2013 US Census estimates were used 
as the denominator to match the case data (16). Information about patient demographic 
characteristics, specifically sex, race, and age group was used where available. Race was 
classified as white, black, or other, while age was categorized as 18–49, 50–79, and ≥80 
years old. For all cases, the patient's city of residence at enrollment or city identified in the 
national data was abstracted. Because of the Registry's case ascertainment methods and data 
structure, city was the smallest geographic resolution available.
Multidisciplinary ALS clinics (MDC)
Three ALS organizations currently fund and operate MDCs throughout the US to provide 
specialty care to people with the disease: the ALS Association (ALSA), the Muscular 
Dystrophy Association (MDA), and the Les Turner ALS Foundation (LTAF). These 
organizations provided ATSDR a list of their respective MDCs that were in operation during 
2013 to match the case data time-period. Collectively, there were 72 different MDCs in 
operation during 2013. Of these, most were maintained and operated individually by MDA 
(n = 39, 54.2%) and ALSA (n = 27, 37.5%), five (6.9%) were joint ALSA/MDA were joint 
ALSA/MDA MDCs, and the remaining one belongs to LTAF (Supplemental table).
While each organization has its own specific criteria of what constitutes an MDC, they all 
largely operate using uniform care, adhere to the practice parameters set out by the 
American Academy of Neurology (17), participate in ALS-related research, and undergo a 
certification process. The MDCs used in this analysis include ALSA's Certified Treatment 
Centers of Excellence, MDA's designated ALS Care Centers, and LTAF's Lois Insolia ALS 
Clinic. Although ALSA and MDA operate other centers (e.g. ALSA's Recognized Treatment 
Centers and MDA's Care Centers), the focus of this paper is on centers that are staffed by 
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multidisciplinary teams of health professionals skilled in the diagnosis and medical 
management of ALS, including symptom control, medical interventions and therapies to 
help maintain the highest possible quality of life.
Data geocoding and analysis
For each ALS case, the patient's city was geocoded using the Google Maps Geocoding API 
(18). Of the total 15,908 cases, 15,633 (98.3%) were successfully geocoded to the city of 
residence. Google's geocoder uses multiple components to geocode to either a 
neighborhood, locality, or administrative area when a street address is not provided. Cases 
not geocoded were due to incorrectly added city or missing data. All 72 (100%) MDC 
clinics were geocoded successfully. ArcGIS 10.3 geographic information system (GIS) 
software (19) was then used to (1) map the geocoded cases and MDCs; and (2) calculate the 
proximity of cases to the nearest MDC, categorized by four distance categories (0–25, >25–
50, >50–100, and >100 miles). For regional analysis, the US was grouped into four regions 
as specified by the US Census Bureau: Northeast, South, Midwest, and West (20).
Data were largely descriptive and analyzed using SAS software, version 9.3 (21). 
Additionally, a Chi-square statistical test was used to compare (1) the demographics of the 
geocoded cases (i.e. sex, race, and age group) by MDC distance categories; and (2) the 
demographics of the non-geocodable cases with those of the geocoded cases. Unknown and 
missing cases for sex, race, and age groups were excluded from the Chi-square analysis 
comparing the demographics of the geocoded cases by MDC distance categories.
Results
MDC locations
The 72 MDCs were distributed in 30 different states, with some states and large 
metropolitan areas having multiple MDCs. More than half of the MDCs (n=42, 58.3%) are 
east of the Mississippi River. Of the four Census regions (Map), the largest number of 
MDCs are located in the South (n=20, 27.8%), followed by the Northeast (n=19, 26.4%), 
Midwest (n=17, 23.6%), and the West (n=16, 22.2%). When analyzing MDCs by 
population, the Northeast has the highest proportion of MDCs per 1,000,000 population 
(0.34), followed by the Midwest (0.25), West (0.22), and the South (0.16). The individual 
states with the greatest numbers of MDCs are California and New York (n=7, 9.7%), 
followed by Michigan and Texas (n=5, 7.0%). The three most populated cities with MDCs 
are New York City (n=8,305,061 population with 3 MDCs), Los Angeles (n=3,843,507 
population with 1 MDC), and Chicago (n=1,194,337 population with 2 MDCs).
ALS case demographics and distribution
Of the 15,633 geocoded cases, most were male, white, and in the 50–79 year age range 
(Table 1). The mean age of cases at diagnosis was 63.5 years. Cases were distributed in all 
50 states and DC and Puerto Rico (Map). More than half of the cases (n = 9515, 60.9%) are 
east of the Mississippi River. Of the four Census regions, most cases are in the South (n = 
5724, 36.7%), followed by the Midwest (n = 3824, 24.5%), West (n = 3171, 20.2%), and the 
Northeast (n = 2888, 18.5%). The Midwest has the highest rate of cases per region with a 
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rate of 5.7 per 100,000 population, followed by the Northeast (5.2), South (4.7), and the 
West (4.3). The individual states with the greatest numbers of cases were California 
(n=1450, 9.3%), Florida (n=1010, 6.5%), and Texas (n = 976, 6.2%). Geocoded cases were 
younger compared with non-geocodable cases (p< 0.0001), but there was no statistically 
significant difference for sex or race.
Proximity of cases to MDCs
For overall case-to-MDC proximity, about 45% of all geocoded persons with ALS in the US 
lived>50 miles from an MDC, and this includes approximately a quarter (24.6%) who 
lived>100 miles from an MDC (Table 2). In the continental US, the West had the furthest 
case-to-MDC proximity average. Similarly, when examining state level continental US 
cases, ALS cases in Montana resided the greatest distance from an MDC as the furthest 
case-to-MDC distance was approximately 600 miles.
When case-to-MDC proximity was evaluated by sex, there was no statistically significant 
difference among males vs. females at any distance category (0–25, >25–50, >50 100, >100 
miles). Regarding race, a higher percentage of Blacks and Other lived closer to MDCs at the 
0-25 mile range compared with Whites (Table 2). There was a statistically significant 
difference for distance categories among Whites vs. Blacks and Whites vs. Other (p<0.001), 
in addition to Blacks vs. Other (p<0.05). For age, a higher percentage of those ≥80 years 
lived within 0–50 miles of an MDC compared with the other two age groups. There were 
statistically significant differences for distance groupings among those 18–49 years vs. those 
≥80 years, and those 50–79 vs. ≥80 years (p<50.05). However, there was no statistically 
significant difference between those 18–49 years compared with those 50–79 years.
Discussion
This spatial analysis is the first to map population-based ALS prevalence cases for the entire 
US and examine their proximity to the closest multidisciplinary ALS clinic (MDC). 
Knowing case counts, demographic information, and proximity to specialty care clinics can 
help inform healthcare professionals and ALS organizations on how to better allocate 
clinical resources to meet the needs of those living with the disease, especially ones who do 
not have convenient access to MDCs or other relevant treatment facilities.
Data from this analysis show that those living with ALS tend to be white, male and in older 
age groups, which is consistent with other findings (4,22,23). While cases were distributed 
in all 50 states, overall they tended mostly to cluster in large metropolitan areas. Although 
the prevalence rates were fairly consistent across the four Census regions, three states 
(California, Florida, and Texas) contained almost a quarter of all ALS cases. This is not 
necessarily unexpected given that these are among the top five most populated states, have 
about 26% of the overall US population and, furthermore, these states have a high 
percentage of people who fit the ALS age demographic (e.g. age ≥50 years) (24). 
Comparing demographics among the geocoded cases versus those that were non-
geocodable, revealed that age was significantly different among the two groups. However, 
this difference is unlikely to change the overall interpretation because the number of non-
geocodable cases was small (<2%).
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Almost half of all geocoded persons with ALS in the US lived>50 miles from an MDC. 
While this finding is largely dependent on what part of the country the case lives in and 
whether or not the area was considered rural, there are several factors that appear to correlate 
with case-to-MDC proximity, such as race and age. For race, a statistically significantly 
higher percentage of Blacks and those classified as Other lived closer to MDCs at the 0–25 
mile range compared with Whites. This, perhaps, is due to a generally higher percentage of 
ethnic and racial minorities living in urban areas (25), which are where MDCs are located. 
Conversely, Whites historically have moved further out of urban areas and more into the 
suburbs (26), away from MDCs. For age, those in the highest age category (≥80 years) lived 
closer to MDCs at the 0–25 and >25–50 mile range compared with those in the younger age 
categories. While recent findings show that the percentage of older adults is higher in rural 
areas than in the rest of the US (27), it is possible that some ALS patients, once diagnosed, 
move closer to areas that provide better care (e.g. an urban area with an MDC). In addition, 
it is also possible that those living in rural areas are underdiagnosed because of the lack of 
specialty medical services, and are therefore not captured by our case ascertainment methods 
leading to the higher prevalence of older adults living closer to MDCs.
Large ALS organizations in the US (i.e. ALSA, MDA, and LTAF) have spent decades 
establishing MDCs to provide high quality care to people living with the disease. This 
analysis shows that the collective MDC network provides broad geographic coverage across 
a vast swathe of states. However, the data also show that there are areas of the country where 
MDC coverage is lacking, such as the upper states in the West and Midwest (e.g. Montana, 
North Dakota). While the lack of MDCs in these areas is likely due to healthcare supply and 
demand (e.g. low case counts, sparse population density, absence of neurologists), ALS 
organizations are continuing to establish more MDCs around the country to expand access to 
care.
In localities that are underserved by MDCs, these ALS organizations are also using 
alternative outreach models that allow for continued expansion of services to those in need. 
Examples include providing transportation services for patients to MDCs and offering 
expertise to patients from clinicians through email, telephone, and FaceTime visits. Such 
services are important to help provide a full continuum of care, especially since the burden 
of travel increases as the disease progresses. Other potential options for expanding access to 
care may include issuing wearable devices (e.g. smart watches) to patients for monitoring 
vital statistics (28), establishing satellite or mobile health clinics that focus specifically on 
persons with ALS and other debilitating diseases (29), and offering continuing medical 
education (CME) online to rural neurologists on how to diagnose and treat persons with 
ALS, especially if their clinics see very few ALS patients (30).
Another promising model currently being used by some MDCs that has widespread potential 
to increase further access to care is telemedicine. Telemedicine allows MDC clinicians and 
others to connect with ALS patients anywhere via a web-cam and a secure internet 
connection. A national movement in this direction would be facilitated by the creation of 
payor ‘telemedicine-in-the- home’ billing codes and changes in licensure laws that currently 
restrict crossing state lines with this technology. Studies suggest that persons with ALS who 
use telemedicine have decreased emergency room visits and hospital admissions, save on 
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travel-related expenses, and are generally satisfied with their care, among other benefits (31–
33). However, even telemedicine has its limitations (e.g. lack of internet and/or computer 
access in rural areas) and may not be able to address all the medical needs of an ALS 
patient, especially where a physical examination is needed.
Limitations
The findings in this analysis are subject to some limitations. First, because ALS is not a 
notifiable disease in the US ensuring that all cases are captured in the Registry is 
challenging. Therefore, the possibility of under-ascertainment exists, especially for harder to 
reach minority and/or rural populations with ALS. Secondly, not all people with ALS go to 
MDCs. For example, some people may elect to be treated by their local health care provider, 
while others may go to non-MDCs operated by ALSA or MDA (e.g. ALSA's Recognized 
Treatment Centers and MDA's Care Centers), and yet others may seek no treatment at all. 
Similarly, veterans with ALS may seek treatment at VA hospitals; however, these facilities 
were excluded from this analysis because it is unclear which ones have specialists available 
for persons with the disease, and non-veterans cannot use these facilities. Furthermore, case 
location is not necessarily an exact address because the National ALS Registry does not 
collect street addresses of patients, only city of residence at enrollment or city listed in the 
national databases. Thus, this analysis used distance categories to decrease the 
misclassification of not having exact street addresses. Similarly, case distance was plotted 
via a straight line to the nearest MDC. Therefore, it is likely the distances are longer when 
actually driving street routes.
Conclusion
ALS is a rapidly fatal disease that can impact anyone, but particularly those who are white, 
male, and in older age groups. Multidisciplinary ALS clinics (MDCs) have been established 
by large ALS organizations in the US over the past few decades to provide specialty care to 
people living with the disease. Collectively, these MDCs provide broad geographic 
coverage, especially in urban areas. However, roughly half of the almost 16,000 individuals 
in the US with ALS live>50 miles from an MDC. While steps are currently being taken by 
these ALS organizations to increase access to care for people with ALS, more options, such 
as tele-medicine, may benefit those in rural, non-urban settings. Having better access to care, 
whether at MDCs or through other modalities, is likely key to increasing survivability and 
obtaining appropriate end-of-life treatment and support for persons living with this deadly 
disease.
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